High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment
Open Access
- 1 March 2003
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 17 (3) , 576-584
- https://doi.org/10.1038/sj.leu.2402844
Abstract
In this study, we analyzed the influence of cell cycle status manipulations of leukemic cells on Fas-mediated apoptosis using the GM-CSF-dependent human myeloid leukemia cell line AML-193 as a model. GM-CSF and long-term treatment with interferon-gamma (IFN-γ) or interferon-alpha (IFN-α) were used to manipulate the cell cycle status. Control cells were GM-CSF deprived, nonproliferating cells. IFN-γ or IFN-α treatment did not induce proliferation in control cells, but resulted in recruitment of cells from resting G0 phase into activated G1 phase. Using agonistic anti-Fas antibodies (FAS18), we demonstrated that this shift from G0 to G1 was accompanied by a 2.5-fold increase in Fas sensitivity. A similar increase in sensitivity to FAS18 could be obtained by induction of proliferation with GM-CSF. Quantitative FACS analysis of surviving cells after FAS18-induced apoptosis showed deletion of the G1 compartment, but complete protection of resting G0 cells. Cells in S or G2/M phase were relatively protected against Fas induction. In conclusion, sensitivity to Fas-mediated apoptosis was restricted to cells in G1 phase of the cell cycle, and can be increased by treatment of cells with interferons. By this mechanism, interferon treatment may render leukemic cells more susceptible to lysis by T cells during immunotherapeutic interventions.Keywords
This publication has 21 references indexed in Scilit:
- Donor lymphocyte infusion followed by interferon-α plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantationLeukemia Research, 2001
- Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and ToxicitiesThe Oncologist, 2001
- Recombinant IFN-α (2b) Increases the Expression of Apoptosis Receptor CD95 and Chemokine Receptors CCR1 and CCR3 in Monocytoid CellsThe Journal of Immunology, 1999
- Cell death induced by the Fas/Fas ligand pathway and its role in pathologyImmunology & Cell Biology, 1999
- T cells recognizing leukemic CD34 + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantationProceedings of the National Academy of Sciences, 1998
- Donor Lymphocyte Infusion for the Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantationLeukemia & Lymphoma, 1998
- Apoptosis by Death FactorCell, 1997
- Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: A new view of the cell cycleExperimental Cell Research, 1990
- Mechanism of Action of Antitumor Drug Etoposide: A ReviewJNCI Journal of the National Cancer Institute, 1988
- Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67Journal of Immunological Methods, 1986